AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

3.010

-0.110-3.53%

Volume:696.51K

Turnover:2.07M

Market Cap:244.55M

PE:-2.86

High:3.150

Open:3.140

Low:2.900

Close:3.120

52wk High:6.500

52wk Low:2.040

Shares:81.25M

Float Shares:67.00M

Volume Ratio:4.71

T/O Rate:1.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.051

EPS(LYR):-1.186

ROE:8.20%

ROA:-3.14%

PB:0.63

PE(LYR):-2.54

Loading ...

Overview Company News Filings

New South Wales Supreme Court Awards Mayne Pharma Group Over AU$13 Million in Legal Costs Following Cosette Pharmaceuticals Proceedings; Shares Up 6%

MT Newswires Live

3 ASX Penny Stocks With Market Caps Over A$70M To Consider

Simply Wall St.

Mayne Pharma Group Ltd - Court Is Expected to Make Orders to Give Effect to Judgement Shortly

THOMSON REUTERS

Mayne Pharma Group Ltd - All Figures in AUD

THOMSON REUTERS

Mayne Pharma Group to Expand Wholly-Owned Specialty Pharmacy in Kentucky

MT Newswires Live

Mayne Pharma Group Ltd-Mayne Pharma Announces Expansion of Adelaide Apothecary

THOMSON REUTERS

BRIEF-Mayne Pharma Provides Further Details On Equity Instruments To Be Issued To CEO

Mayne Pharma - Confirms That CEO Is Not Involved in Any Remuneration Decisions Regarding Issue of Incentives to Him

THOMSON REUTERS

Mayne Pharma Group Ltd-Further Details Re Equity Instruments to Be Issued to CEO

THOMSON REUTERS

BRIEF-Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 Million

Mayne Pharma Group Reports Higher Fiscal Q3 Revenue

MT Newswires Live

Stock Track | Mayne Pharma Group Soars 5.58% Intraday on Strong Revenue, Tariff Immunity and Buy-Back Plans

Mayne Pharma Group Ltd: No Material Earnings Impact From US Tariff Proclamation on 7 April

THOMSON REUTERS

Mayne Pharma Group - Continues to Examine Capital Allocation Strategies, May Include on-Market Share Buy-Back

THOMSON REUTERS

Maywood Acquisition Closes $100 Million IPO

MT Newswires Live

BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs

BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs

Mayne Pharma - Entire US Dermatology Generics Portfolio Expected to Be Exempt From Tariffs Under Proclamation

THOMSON REUTERS

Mayne Pharma Group Ltd - Myx Expects No Material Impact From US S232 Tariffs

THOMSON REUTERS

Mayne Pharma Group - Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.etasphere.com/stock/MYX.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":3.01,"timestamp":1787897520000,"preClose":3.12,"halted":0,"volume":696512,"delay":0,"changeRate":-0.03525641025641036,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81245827,"eps":-1.051059,"marketStatus":"Not Yet Opened","change":-0.11,"latestTime":"08-28 16:12:00 AEST","open":3.14,"high":3.15,"low":2.9,"amount":2065147,"amplitude":0.080128,"askPrice":3.09,"askSize":630,"bidPrice":2.97,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.051059,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":3.12,"openAndCloseTimeList":[[1787875200000,1787896800000]],"volumeRatio":4.709210421340299,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":3.12,"auctionPrice":3.01,"auctionVolume":3596,"auction":3,"marketStatus":"盘后竞价","timestamp":1787897406713}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-3.14%","roe":"8.20%","lyrEps":-1.185711,"volumeRatio":4.709210421340299,"shares":81245827,"dividePrice":0,"high":3.15,"amplitude":0.080128,"preClose":3.12,"low":2.9,"week52Low":2.04,"pbRate":"0.63","psRate":"0.64","week52High":6.5,"institutionHeld":0,"latestPrice":3.01,"committee":-0.354839,"eps":-1.051059,"divideRate":0,"volume":696512,"delay":0,"ttmEps":-1.051059,"open":3.14,"prevYearClose":3.11,"prevWeekClose":3.01,"prevMonthClose":2.66,"prevQuarterClose":2.79,"fiveDayClose":3.26,"twentyDayClose":2.66,"sixtyDayClose":2.21,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637628443","title":"New South Wales Supreme Court Awards Mayne Pharma Group Over AU$13 Million in Legal Costs Following Cosette Pharmaceuticals Proceedings; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637628443","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637628443?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:09","pubTimestamp":1779419376,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  is entitled to nearly AU$13.3 million in legal costs following court proceedings against Cosette Pharmaceuticals in the New South Wales Supreme Court last year, according to a Friday filing with the Australian bourse.The company initiated proceedings against Cosette Pharmaceuticals in June 2025 in relation to Cosette's purported termination of the scheme implementation deed signed by the two parties in February 2025, the filing said.The court ruled in favor of the company in October 2025 and made an adverse costs order against Cosette, per the filing.Mayne Pharma Group shares rose 6% in midday trade on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637139346","title":"3 ASX Penny Stocks With Market Caps Over A$70M To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2637139346","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637139346?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:09","pubTimestamp":1779415747,"startTime":"0","endTime":"0","summary":"It’s looking like we could be in for a green finish to the week with ASX futures tipping a rise of 0.5% for the ASX pre-market after oil prices dipped again overnight and gold travelled back above US$4,500 an ounce. While 'penny stocks' might seem like an outdated term, they continue to offer intriguing possibilities for investors seeking affordable entry points and growth potential. In this article, we highlight three penny stocks that showcase financial strength and resilience, offering...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3071000-choice2-main-header/1585186751359","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3071000-choice2-main-header/1585186751359"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-mxi/maxiparts-shares/news/3-asx-penny-stocks-with-market-caps-over-a70m-to-consider","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-mxi/maxiparts-shares/news/3-asx-penny-stocks-with-market-caps-over-a70m-to-consider","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","MXI.AU","CAF.AU","BK7062","MYX.AU","BK7096","BK7077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637661653","title":"Mayne Pharma Group Ltd - Court Is Expected to Make Orders to Give Effect to Judgement Shortly","url":"https://stock-news.laohu8.com/highlight/detail?id=2637661653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637661653?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:08","pubTimestamp":1779412127,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUE6MPXLJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637366157","title":"Mayne Pharma Group Ltd - All Figures in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2637366157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637366157?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:08","pubTimestamp":1779412127,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUE6MPXLJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636017673","title":"Mayne Pharma Group to Expand Wholly-Owned Specialty Pharmacy in Kentucky","url":"https://stock-news.laohu8.com/highlight/detail?id=2636017673","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636017673?lang=en_us&edition=fundamental","pubTime":"2026-05-18 08:50","pubTimestamp":1779065418,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group's (ASX:MYX) wholly-owned specialty pharmacy, Adelaide Apothecary, will relocate and expand its fulfillment operations to a new facility in Lexington, Kentucky, according to a Monday","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636148530","title":"Mayne Pharma Group Ltd-Mayne Pharma Announces Expansion of Adelaide Apothecary","url":"https://stock-news.laohu8.com/highlight/detail?id=2636148530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636148530?lang=en_us&edition=fundamental","pubTime":"2026-05-18 06:57","pubTimestamp":1779058664,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260517:nTUE2X9MQ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631574153","title":"BRIEF-Mayne Pharma Provides Further Details On Equity Instruments To Be Issued To CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2631574153","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631574153?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:45","pubTimestamp":1777513500,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Provides Further Details On Equity Instruments To Be Issued To CEOApril 30  - Mayne Pharma Group Ltd MYX.AX:FURTHER DETAILS RE EQUITY INSTRUMENTS TO BE ISSUED TO CEOCONFIRMS THAT CEO IS NOT INVOLVED IN ANY REMUNERATION DECISIONS REGARDING ISSUE OF INCENTIVES TO HIMFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUE8K62YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631752031","title":"Mayne Pharma - Confirms That CEO Is Not Involved in Any Remuneration Decisions Regarding Issue of Incentives to Him","url":"https://stock-news.laohu8.com/highlight/detail?id=2631752031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631752031?lang=en_us&edition=fundamental","pubTime":"2026-04-30 06:23","pubTimestamp":1777501382,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE8K62YS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631312520","title":"Mayne Pharma Group Ltd-Further Details Re Equity Instruments to Be Issued to CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2631312520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631312520?lang=en_us&edition=fundamental","pubTime":"2026-04-30 06:23","pubTimestamp":1777501382,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE8K62YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631556330","title":"BRIEF-Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631556330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631556330?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:23","pubTimestamp":1777425830,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Posts QTRLY Underlying EBITDA Of -A$1.4 MillionApril 29  - Mayne Pharma Group Ltd MYX.AX:QTRLY  UNDERLYING EBITDA OF -A$1.4 MILLIONNO MATERIAL EARNINGS IMPACT FROM US TARIFF PROCLAMATION ON 7 APRILQTRLY REVENUE A$85.2 MILLIONCONTINUES TO EXAMINE CAPITAL ALLOCATION STRATEGIES, MAY INCLUDE ON-MARKET SHARE BUY-BACKFurther company coverage: MYX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41B152:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553185","title":"Mayne Pharma Group Reports Higher Fiscal Q3 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553185","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553185?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:41","pubTimestamp":1777423296,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.Mayne Pharma said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150217046","title":"Stock Track | Mayne Pharma Group Soars 5.58% Intraday on Strong Revenue, Tariff Immunity and Buy-Back Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1150217046","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150217046?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:17","pubTimestamp":1777421842,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd's stock surged 5.58% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical company.The sharp rise appears to be driven by several...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631530545","title":"Mayne Pharma Group Ltd: No Material Earnings Impact From US Tariff Proclamation on 7 April","url":"https://stock-news.laohu8.com/highlight/detail?id=2631530545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631530545?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:33","pubTimestamp":1777419228,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B152:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631530528","title":"Mayne Pharma Group - Continues to Examine Capital Allocation Strategies, May Include on-Market Share Buy-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2631530528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631530528?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:33","pubTimestamp":1777419228,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B152:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230683","title":"Maywood Acquisition Closes $100 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230683","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230683?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:26","pubTimestamp":1776284780,"startTime":"0","endTime":"0","summary":"Maywood Acquisition  said late Wednesday it has completed its initial public offering of 10 million units at $10 per unit, resulting in gross proceeds of $100 million.Its units are listed on Nasdaq under the symbol \"MYXXU\".Each unit consists of one Class A ordinary share, one right entitling the holder to receive one-fourth of one Class A ordinary share upon the completion of an initial business combination, and one warrant to purchase one Class A ordinary share for $11.50 per share, subject to adjustment, according to the company.Once the securities comprising the units begin trading separately, the ordinary shares, rights and warrants are expected to be listed on Nasdaq under the symbols \"MYX,\" \"MYXXR\" and \"MYXXW,\" respectively.An aggregate of $100 million from IPO net proceeds and a simultaneous private placement of units was placed in a trust, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","SPCX","IPOS","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625985237","title":"BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625985237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625985237?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:15","pubTimestamp":1775528150,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 TariffsApril 7  - Mayne Pharma Group Ltd MYX.AX:MYX EXPECTS NO MATERIAL IMPACT FROM US S232 TARIFFSENTIRE US DERMATOLOGY GENERICS PORTFOLIO EXPECTED TO BE EXEMPT FROM TARIFFS UNDER PROCLAMATIONNO MATERIAL IMPACT EXPECTED FOR MAYNE PHARMA'S WOMEN'S HEALTH PORTFOLIO FROM US S232 TARIFFSSEVERAL OF COMPANY'S BRANDED DERMATOLOGY PRODUCTS MAY BE SUBJECT TO NEW SECTION 232 TARIFFSMINIMAL IMPACT EXPECTED IN SALISBURY, SOUTH AUSTRALIA MANUFACTURING FACILITY AS MOST EXPORT PRODUCTS TO US ARE GENERIC PRODUCTSFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625598338","title":"BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625598338","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625598338?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:04","pubTimestamp":1775523848,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs** Mayne Pharma MYX.AX gains as much as 4.7% to A$2.45, highest since April 2** Stock marks biggest intraday pct gain since April 1** Co expects no material impact to FY27 earnings profile from New Section 232 tariff proclamation announced by Donald Trump** Trump signed executive order imposing 100% tariffs on branded pharma products imported into U.S. unless makers agree to government drug pricing deals or commit to making their products domestically** YTD, MYX down 21.5%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q01Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625979600","title":"Mayne Pharma -  Entire US Dermatology Generics Portfolio Expected to Be Exempt From Tariffs Under Proclamation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625979600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625979600?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944600","title":"Mayne Pharma Group Ltd -  Myx Expects No Material Impact From US S232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944600?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625600102","title":"Mayne Pharma Group -  Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2625600102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625600102?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}